The global deuterium-substituted drugs market size was valued at USD 241.2 million in 2022. The market is projected to grow from USD 241.2 million in 2022 to USD 326.9 million by 2030, exhibiting a CAGR of 5.20% during the forecast period.
A medication that has been deuterated is a small molecule in which one or more chemical element atoms have been swapped out for isotopes. Isotope replacement is the smallest structural change made to a molecule because the physical properties of the deuterium-heavy chemical element, hydrogen atom, isotope, and hydrogen are almost constant. The market for deuterium-substituted drugs is anticipated to expand dramatically over the next few years as the prevalence of dementia and Alzheimer's disease rises. Additionally, the market for Deuterium-substituted drugs is being benefited by the rise in government-backed measures aimed at setting regulations to stop the global rise in consciousness.

Read Comprehensive Overview of Report @

Rising Prevalence of Alzheimer's Disease to Promote Market Growth

The expansion of the deuterium-substituted drugs market is anticipated to be fueled by the increasing prevalence of Alzheimer's disease and the approval of disease-modifying treatments. According to the NCBI, around 6.2 million Americans 65 and older had Alzheimer's disease in 2021; this number is predicted to rise to almost 13.8 million by 2060. Due to their greater life expectancy, women are more likely than men to be diagnosed with Alzheimer's. Additionally, Alzheimer's disease quickly overtakes other neurodegenerative illnesses as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention. Thus, the growing prevalence of Alzheimer's disease fuels the growth of the deuterium-substituted drugs market.


  • Teva
  • Zelgen
  • Bristol-Myers Squibb
  • Alkeus
  • Avanir
  • Retrotope
  • Vertex
  • Concert
  • Jazz Pharmaceuticals

Read More News :